MS Clinical Trials in Georgia
19 active trials · 10 recruiting
19 active multiple sclerosis clinical trials have at least one study site in Georgia, 10 of them currently recruiting participants. Trials are listed from ClinicalTrials.gov and cover disease-modifying therapies, symptom treatments, rehabilitation and imaging studies.
Eligibility, contact details and the exact site address are on each trial's ClinicalTrials.gov record, linked from every trial page. MS Buddy also lists 10 MS treatment centers in Georgia; many trial sites are run from those centers, and your neurologist is the best first person to ask about joining a study.
Active MS trials with sites in Georgia
RecruitingNA
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
Sponsor: SetPoint Medical Corporation
Procedure/Surgery: Implant Procedure · Disease-Modifying Therapies (DMTs)
4 states60 participantsDetails ›
RecruitingPhase 1
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Sponsor: National Cancer Institute (NCI)
Biospecimen Collection · Nivolumab
19 states300 participantsDetails ›
RecruitingPhase 3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Sponsor: Sanofi
Frexalimab · Teriflunomide
35 states1600 participantsDetails ›
Recruiting
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
Sponsor: TG Therapeutics, Inc.
No intervention
4 states16 participantsDetails ›
Recruiting
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Sponsor: TG Therapeutics, Inc.
No Intervention
29 states500 participantsDetails ›
RecruitingPhase 3
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Sponsor: Sanofi
Frexalimab · Placebo
38 states900 participantsDetails ›
RecruitingPhase 1
Effects of Ublituximab on Motor Functions in Multiple Sclerosis
Sponsor: Georgia State University
Ublituximab
1 state25 participantsDetails ›
RecruitingNA
Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis
Sponsor: Georgia State University
Perturbation Training · Treadmill Walking
1 state64 participantsDetails ›
RecruitingNA
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
Sponsor: Emory University
StableEyes
1 state138 participantsDetails ›
RecruitingPhase 1
A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis
Sponsor: ImStem Biotechnology
IMS001
3 states30 participantsDetails ›
By invitation onlyNA
Effects of Stimulation Patterns of Deep Brain Stimulation
Sponsor: Duke University
Therapeutic Stimulation Patterns · Symptogenic Stimulation Patterns
3 states180 participantsDetails ›
Closed to new patientsPhase 4
Effects of Ocrevus in Relapsing Multiple Sclerosis
Sponsor: Georgia State University
Ocrelizumab · Platform
1 state60 participantsDetails ›
Closed to new patientsPhase 3
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
Sponsor: Novartis Pharmaceuticals
Ofatumumab approved dose · Ofatumumab new dose
24 states196 participantsDetails ›
Closed to new patientsPhase 3
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Sponsor: Novartis Pharmaceuticals
Ofatumumab · Tetanus toxoid (TT) containing vaccin…
32 states1882 participantsDetails ›
Closed to new patientsPhase 3
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Sponsor: Sanofi
Tolebrutinib · Placebo
27 states2500 participantsDetails ›
Closed to new patientsPhase 3
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
Sponsor: Hoffmann-La Roche
Ocrelizumab
26 states1300 participantsDetails ›
Closed to new patients
Biobank For MS And Other Demyelinating Diseases
Sponsor: Accelerated Cure Project for Multiple Sclerosis
9 states3226 participantsDetails ›
Closed to new patientsNA
MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect
Sponsor: Ad scientiam
MSCopilot® Detect mobile application
10 states336 participantsDetails ›
Closed to new patientsPhase 2
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
Sponsor: Immunic AG
IMU-838 · Placebo matching IMU-838
6 states450 participantsDetails ›
